Back to Search
Start Over
Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention
- Source :
- Dovey de la Cour, C, Guleria, S, Nygård, M, Trygvadóttir, L, Sigurdsson, K, Liaw, K-L, Hortlund, M, Lagheden, C, Hansen, B T, Munk, C, Dillner, J & Kjaer, S K 2019, ' Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention ', Cancer Medicine, vol. 8, no. 2, pp. 839-849 . https://doi.org/10.1002/cam4.1961, Cancer Medicine
- Publication Year :
- 2019
- Publisher :
- Wiley, 2019.
-
Abstract
- Publisher's version (útgefin grein)<br />It is valuable to establish a population‐based prevaccination baseline distribution of human papillomavirus (HPV) types among women with high‐grade cervical intraepithelial neoplasia (CIN) grade 2 or 3 and cervical cancer in order to assess the potential impact of HPV vaccination. In four countries (Denmark, Norway, Sweden, and Iceland), we collected consecutive series of cervical cancers (n = 639) and high‐grade precancerous cervical lesions (n = 1240) during 2004‐2006 before implementation of HPV vaccination and subjected the specimens to standardized HPV genotyping. The HPV prevalence was 82.7% (95% confidence interval [CI] 79.0‐86.4) in CIN2, 91.6% (95% CI 89.7‐93.5) in CIN3, and 86.4% (95% CI 83.7‐89.1) in cervical cancer. The most common HPV types in CIN2/3 were HPV16 (CIN2: 35.9%, 95% CI 31.2‐40.6; CIN3: 50.2%, 95% CI 46.8‐53.6) and HPV31 (CIN2: 10.9%, 95% CI 7.8‐13.9; CIN3: 12.1%, 95% CI 9.9‐14.3), while HPV16 and HPV18 were the most frequent types in cervical cancer (48.8%, 95% CI 44.9‐52.7 and 15.3%, 95% CI 12.5‐18.1, respectively). The prevalence of HPV16/18 decreased with increasing age at diagnosis in both CIN2/3 and cervical cancer (P < 0.0001). Elimination of HPV16/18 by vaccination is predicted to prevent 42% (95% CI 37.0‐46.7) of CIN2, 57% (95% CI 53.8‐60.5) of CIN3 and 64% (95% CI 60.3‐67.7) of cervical cancer. Prevention of the five additional HPV types HPV31/33/45/52/58 would increase the protection to 68% (95% CI 63.0‐72.2) in CIN2, 85% (95% CI 82.4‐87.2) in CIN3 and 80% (95% CI 77.0‐83.2) in cervical cancer. This study provides large‐scale and representative baselines for assessing and evaluating the population‐based preventive impact of HPV vaccination.<br />We thank Cecilia Wahlström and Kia Sjölin for assistance with the HPV genotyping. SKK received lecture fee from Merck and Sanofi Pasteur MSD, scientific advisory board fee from Merck, and unrestricted research grants through her institution from Merck. JD reports having received research grants to his institution for the funding of the study. CM received lecture fees and travel grants from Sanofi Pasteur MSD. CL and MH report that their institution received a grant from Merck. KLL is a full‐time employee of Merck & Co. Inc and owns stocks and options of Merck. MN received research grants from MSD Norway/Merck through the affiliating institute. CDC, SG, LT, KS, and BTH report no conflicts of interest.
- Subjects :
- 0301 basic medicine
Cancer Research
cervical cancer
Veirur
Prevalence
Uterine Cervical Neoplasms
Leghálskrabbamein
0302 clinical medicine
Epidemiology
DNA, Viral/analysis
human papillomavirus
Papillomaviridae
Original Research
Cervical cancer
education.field_of_study
Middle Aged
female genital diseases and pregnancy complications
Vaccination
Nordic countries
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Female
Cancer Prevention
Adult
Human papillomavirus
medicine.medical_specialty
Norðurlönd
prevalence
Population
Uterine Cervical Neoplasms/epidemiology
Scandinavian and Nordic Countries
cervical intraepithelial neoplasia
Cervical intraepithelial neoplasia
03 medical and health sciences
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
education
Cervix
nordic countries
business.industry
Papillomavirus Infections
Cancer
medicine.disease
Scandinavian and Nordic Countries/epidemiology
030104 developmental biology
Tíðni
Papillomavirus Infections/epidemiology
DNA, Viral
Papillomaviridae/genetics
business
Subjects
Details
- ISSN :
- 20457634
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....e5cff27f68f83e8df8118d6339565cac